Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevuparin placebo-controlled LPS challenge study in healthy volunteers
NL-OMON52250Completed
- Sponsor
- Modus Therapeutics
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised trial of sevuparin and enoxaparin in sepsis and septic shock (6 arms), sponsored by Modus Therapeutics. Started Nov 2021; status: completed.
02
Drugs
sevuparinenoxaparin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NL-OMON52250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52250.